Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.43 |
| ▸ | SCN2A | Q99250 | 3/20 | 0.43 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.41 |
| ▸ | APAF1 | O14727 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3450856 | 0.96 | MMP13 (0.52) | MMP13MEN1KMT2ARAB9ANPC1 | |
| SCHEMBL4048359 | 0.87 | NQO2 (0.54) | RAB9ANPC1CHRNA4SMN1; SMN2 | |
| SCHEMBL4047306 | 0.86 | RAB9A (0.44) | MMP13RAB9ANPC1SCN5ASCN2A | |
| SCHEMBL4050262 | 0.83 | RAB9A (0.52) | RAB9ANPC1SCN5ASCN2ASCN10A | |
| SCHEMBL3451181 | 0.82 | SCN5A (0.43) | MMP13RAB9ANPC1SCN5ASCN2A | |
| SCHEMBL3453027 | 0.82 | PTPN1 (0.53) | MMP13MEN1KMT2ARAB9ANPC1 | |
| SCHEMBL4048361 | 0.81 | RAB9A (0.73) | MEN1KMT2ARAB9ANPC1MAPT | |
| SCHEMBL3451824 | 0.79 | RAB9A (0.50) | RAB9ANPC1SCN5ASCN2ASCN10A | |
| SCHEMBL3451493 | 0.76 | RAB9A (0.71) | MEN1KMT2ARAB9ANPC1SCN5A | |
| SCHEMBL3331566 | 0.76 | MMP13 (0.48) | MMP13MEN1KMT2ANPC1SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612074-B2 | Diazabicyclic aryl derivatives as cholinergy ligands | NEUROSEARCH A/S (DK) | 2009-11-03 | — | — | US | claimed |
| EP-1819709-B1 | NOVEL DIAZABICYCLIC ARYL DERIVATIVES AS CHOLINERGY LIGANDS | NEUROSEARCH AS (DK) | 2009-02-11 | — | — | EP | claimed |
| US-20070265271-A1 | Novel Diazabicyclic Aryl Derivatives as Cholinergy Ligands | NEUROSEARCH A/S (DK) | 2007-11-15 | — | — | US | claimed |
| US-7612074-B2 | Diazabicyclic aryl derivatives as cholinergy ligands | NEUROSEARCH A/S (DK) | 2009-11-03 | — | — | US | disclosed |
| EP-1819709-B1 | NOVEL DIAZABICYCLIC ARYL DERIVATIVES AS CHOLINERGY LIGANDS | NEUROSEARCH AS (DK) | 2009-02-11 | — | — | EP | disclosed |
| US-20070265271-A1 | Novel Diazabicyclic Aryl Derivatives as Cholinergy Ligands | NEUROSEARCH A/S (DK) | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265271-A1 | Novel Diazabicyclic Aryl Derivatives as Cholinergy Ligands | CHRNA6, CHRNA10, CHRNA2 | MMP13 2380/4885MEN1 4123/4885KMT2A 1289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.